Diagnostic accuracy of MRI and PSMA PET/CT for detection of histologically confirmed lymph node metastasis in prostate cancer: A systematic review
Abstract
Objective: To compare the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and multiparametric magnetic resonance imaging (mpMRI) for the detection of histologically confirmed pelvic lymph node metastases in patients with intermediate- and high-risk prostate cancer.
Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Embase, and Cochrane Library databases were searched from January 2011 to March 2026. Studies evaluating PSMA PET/CT and/or mpMRI for preoperative pelvic lymph node staging using histopathology as the reference standard were included. Study quality was assessed using the Quality Assessment of Diagnostic Performance Studies-2 tool (QUADAS-2). Pooled sensitivity and specificity were estimated using a hierarchical bivariate random- effects (Reitsma) model, and hierarchical summary receiver operating characteristic (HSROC) curves were generated.
Results: Sixteen studies comprising 1,999 patients met the inclusion criteria. Fourteen studies contributed to the PSMA PET/CT analysis and six studies to the mpMRI analysis. For PSMA PET/CT, pooled sensitivity was 54.6% (95% CI 43.7-65.1%) and pooled specificity was 92.7% (95% CI 90.5-94.4%). The HSROC area under the curve (AUC) was 0.909. For mpMRI, pooled sensitivity was 33.0% (95% CI 18.7-51.3%) and pooled specificity was 94.9% (95% CI 92.2-96.8%), with an HSROC AUC of 0.941. Indirect comparison of pooled estimates suggested that PSMA PET/CT had higher sensitivity and a higher diagnostic odds ratio than mpMRI. However, because these estimates were derived from separate bodies of evidence rather than direct head-to-head comparative studies, this comparison should be interpreted with caution.
Conclusions: PSMA PET/CT demonstrated higher pooled sensitivity than mpMRI while maintaining similarly high specificity for detecting pelvic lymph node metastases. However, the moderate sensitivity of both imaging modalities indicates that a negative PSMA PET/CT scan cannot reliably exclude microscopic nodal disease. Furthermore, this comparison between pooled estimates should be interpreted with caution because it is based on an indirect comparison rather than a formal head-to-head meta-analysis. Consequently, extended pelvic lymph node dissection remains the reference standard for pathological nodal staging in appropriately selected patients, and prospective head-to-head comparative studies are required to define the relative diagnostic performance of PSMA PET/CT and mpMRI.
Keywords
Ethics Approval
No ethics requirement.
Supporting Agencies
The authors did not receive support from any organization for the submitted work.
Data Availability Statement
Not applicable
References
- 1. Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer. JAMA 2025; 333:1433. DOI: https://doi.org/10.1001/jama.2025.0228
- 2. European Association of Urology. EAU Guidelines on Prostate Cancer. Https://UrowebOrg/Guidelines/Prostate-Cancer/Chapter/. Diagnostic-Evaluation 2025.
- 3. Briganti A, Larcher A, Abdollah F, et al. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. Eur Urol 2012; 61:480-7. DOI: https://doi.org/10.1016/j.eururo.2011.10.044
- 4. Thoeny HC, Barbieri S, Froehlich JM, et al. Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges. Radiology 2017; 285:728-43. DOI: https://doi.org/10.1148/radiol.2017161517
- 5. Thoeny HC, Froehlich JM, Triantafyllou M, et al. Metastases in Normal-sized Pelvic Lymph Nodes: Detection with Diffusion-weighted MR Imaging. Radiology 2014; 273:125-35. DOI: https://doi.org/10.1148/radiol.14132921
- 6. Hope TA, Eiber M, Armstrong WR, et al. Diagnostic Accuracy of 68 Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncol 2021; 7:1635. DOI: https://doi.org/10.1001/jamaoncol.2021.3771
- 7. Yang B, Dong H, Zhang S, et al. PSMA PET vs. mpMRI for Lymph Node Metastasis of Prostate Cancer: A Systematic Review and Head-to- Head Comparative Meta-analysis. Acad Radiol 2025;32:2797-814. DOI: https://doi.org/10.1016/j.acra.2024.11.029
- 8. Ingvar J, Hvittfeldt E, Trägårdh E, et al. Assessing the accuracy of (18F)PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res 2022; 12. DOI: https://doi.org/10.1186/s13550-022-00918-7
- 9. Stabile A, Pellegrino A, Mazzone E, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol 2022; 5:1-17. DOI: https://doi.org/10.1016/j.euo.2021.08.001
- 10. Yaxley JW, Raveenthiran S, Nouhaud FX, et al. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/ Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. J Urol 2019; 201:815-20. DOI: https://doi.org/10.1097/JU.0000000000000053
- 11. Szigeti F, Schweighofer-Zwink G, Meissnitzer M, et al. Incremental Impact of (68 Ga)Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. Mol Imaging Biol 2022; 24:50-9. DOI: https://doi.org/10.1007/s11307-021-01650-9
- 12. Franklin A, Yaxley WJ, Raveenthiran S, et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU Int 2021; 127:71-9. DOI: https://doi.org/10.1111/bju.15134
- 13. Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol 2021; 206:52-61. DOI: https://doi.org/10.1097/JU.0000000000001698
- 14. Arslan A, Karaarslan E, Güner AL, et al. Comparing the Diagnostic Performance of Multiparametric Prostate MRI Versus 68Ga-PSMA PET-CT in the Evaluation Lymph Node Involvement and Extraprostatic Extension. Acad Radiol 2022; 29:698-704. DOI: https://doi.org/10.1016/j.acra.2020.07.011
- 15. Tang Y, Ji X, Lin Q, et al. Status of 18F-PSMA-1007-PET/CT compared with multiparametric MRI in preoperative evaluation of prostate cancer. World J Urol 2023; 41:1017-24. DOI: https://doi.org/10.1007/s00345-023-04345-8
- 16. Maestroni UV, Campobasso D, Guarino G, et al. Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit. Chin Clin Oncol 2023; 12:22-22. DOI: https://doi.org/10.21037/cco-23-10
- 17. Xiong Z, Ge Y, Ma S, et al. Comparing the diagnostic value of 68Ga-prostate-specific membrane antigen PET/CT and multiparametric MRI in pelvic lymph node metastasis of locally advanced prostate cancer. Transl Androl Urol 2024; 13:1219-27. DOI: https://doi.org/10.21037/tau-24-15
- 18. Pepe L, Fiorentino V, Curduman M, et al. PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases. In Vivo (Brooklyn) 2024; 38:2880-5. DOI: https://doi.org/10.21873/invivo.13769
- 19. Dinckal M, Ergun KE, Kalemci MS, et al. Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer. Prostate 2025; 85:48-57. DOI: https://doi.org/10.1002/pros.24799
- 20. Arena P, Fasulo V, Gelardi F, et al. An Evaluation of the Diagnostic Accuracy of (68Ga)Ga-PSMA-11 vs. (18F)F-PSMA- 1007 PET/CT for Lymph Node Staging in Patient Candidates for Radical Prostatectomy and Lymph Node Dissection: A Single Institutional Analysis. Diagnostics 2025; 15. DOI: https://doi.org/10.3390/diagnostics15121492
- 21. Eraky A, Tillu N, Ben-David R, et al. Diagnostic Accuracy of (18 F)-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in Intermediate- Risk Prostate Cancer Undergoing Radical Prostatectomy: Is Pelvic Lymph Node Dissection Still Necessary? J Urol 2025; 214:365-73. DOI: https://doi.org/10.1097/JU.0000000000004659
- 22. Talavera Cobo V, Yánez Ruiz CA, Tapia Tapia MD, et al. Diagnostic Accuracy of PSMA-PET/CT vs. mpMRI in Primary Staging of Intermediate- and High-Risk Prostate Cancer. Med Sci (Basel) 2026;14. DOI: https://doi.org/10.3390/medsci14010064
- 23. Daouacher G, Carlsson J, Voulgarakis N, et al. Diagnostic performance of conventional MRI using T1W and T2W for primary lymph node staging in intermediate- and high-risk prostate cancer patients prior to pelvic lymph node dissection. Abdominal Radiology 2025. DOI: https://doi.org/10.1007/s00261-025-05073-w
- 24. Rosales JJ, Betech Antar V, Mínguez F, et al. Comparison of staging using (68Ga)Ga-PSMA-11 PET/CT and histopathological results in intermediate- and high-risk prostate cancer patients treated with radical prostatectomy and pelvic lymph node dissection. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2025; 44:500076. DOI: https://doi.org/10.1016/j.remnie.2024.500076
- 25. Gultekin MH, Demirci E, Turegun FA, et al. The Role of 68GAPSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urol J 2020; 18:58-65.
- 26. Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021; 48:859-73. DOI: https://doi.org/10.1007/s00259-020-05025-0
- 27. Li C, Hu J, Zhang Z, et al. Biparametric MRI of the prostate radiomics model for prediction of pelvic lymph node metastasis in prostate cancers: a two-centre study. BMC Med Imaging 2024; 24. DOI: https://doi.org/10.1186/s12880-024-01372-8
- 28. Madendere S, Kılıç M, Gürses B, et al. Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy? Int J Urol 2024; 31:1269-77. DOI: https://doi.org/10.1111/iju.15553
- 29. Chikatamarla VA, Okano S, Jenvey P, et al. Risk of metastatic disease using (18F)PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Res 2021; 11. DOI: https://doi.org/10.1186/s13550-021-00869-5
- 30. Barbosa ÁRG, Amaral BS, Lourenço DB, et al. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer. Einstein (Sao Paulo) 2022; 20:eAO6599. DOI: https://doi.org/10.31744/einstein_journal/2022AO6599
- 31. Lin Y, Johnson LA, Fennessy FM, Turkbey B. Prostate Cancer Local Staging with Magnetic Resonance Imaging. Radiol Clin North Am 2024; 62:93-108. DOI: https://doi.org/10.1016/j.rcl.2023.06.010
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.